23.25
전일 마감가:
$23.05
열려 있는:
$23.06
하루 거래량:
917.39K
Relative Volume:
0.44
시가총액:
$3.89B
수익:
$890.53M
순이익/손실:
$30.57M
주가수익비율:
129.17
EPS:
0.18
순현금흐름:
$80.53M
1주 성능:
+3.06%
1개월 성능:
+3.33%
6개월 성능:
+24.53%
1년 성능:
+25.34%
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
명칭
Acadia Pharmaceuticals Inc
전화
858-558-2871
주소
12830 EL CAMINO REAL, SAN DIEGO
ACAD을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ACAD
Acadia Pharmaceuticals Inc
|
23.25 | 3.86B | 890.53M | 30.57M | 80.53M | 0.18 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-21 | 업그레이드 | Deutsche Bank | Hold → Buy |
2025-02-11 | 개시 | Deutsche Bank | Hold |
2025-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
2024-10-10 | 재개 | Raymond James | Mkt Perform |
2024-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2024-06-27 | 개시 | BMO Capital Markets | Outperform |
2024-03-12 | 다운그레이드 | Mizuho | Buy → Neutral |
2024-03-12 | 재확인 | Needham | Buy |
2024-01-30 | 개시 | Robert W. Baird | Outperform |
2024-01-24 | 업그레이드 | Needham | Hold → Buy |
2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2023-12-14 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2023-12-13 | 개시 | Citigroup | Buy |
2023-12-12 | 개시 | Deutsche Bank | Buy |
2023-11-06 | 업그레이드 | Mizuho | Neutral → Buy |
2023-10-17 | 개시 | UBS | Buy |
2023-10-10 | 업그레이드 | JP Morgan | Neutral → Overweight |
2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
2022-11-04 | 다운그레이드 | Goldman | Neutral → Sell |
2022-11-01 | 개시 | Loop Capital | Hold |
2022-08-08 | 다운그레이드 | Citigroup | Buy → Neutral |
2022-08-05 | 다운그레이드 | Citigroup | Buy → Neutral |
2022-06-21 | 다운그레이드 | Jefferies | Buy → Underperform |
2022-06-16 | 업그레이드 | Jefferies | Hold → Buy |
2022-03-16 | 업그레이드 | Canaccord Genuity | Hold → Buy |
2022-02-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2022-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
2021-12-21 | 다운그레이드 | Guggenheim | Buy → Neutral |
2021-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2021-09-23 | 재개 | Needham | Hold |
2021-06-10 | 개시 | Berenberg | Hold |
2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2021-04-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
2021-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
2021-04-06 | 다운그레이드 | Jefferies | Buy → Hold |
2021-04-06 | 다운그레이드 | Mizuho | Buy → Neutral |
2021-04-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2021-03-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
2021-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
2021-03-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
2021-03-09 | 재확인 | H.C. Wainwright | Buy |
2021-03-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
2021-03-09 | 다운그레이드 | Stifel | Buy → Hold |
2020-12-16 | 개시 | Mizuho | Buy |
2020-11-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2020-08-25 | 개시 | Raymond James | Outperform |
2020-08-20 | 개시 | Morgan Stanley | Overweight |
2020-07-07 | 업그레이드 | Stifel | Hold → Buy |
2020-04-16 | 개시 | Jefferies | Buy |
2020-03-31 | 업그레이드 | Goldman | Neutral → Buy |
2020-03-06 | 개시 | Citigroup | Buy |
2019-12-16 | 개시 | Guggenheim | Buy |
2019-10-24 | 개시 | Oppenheimer | Perform |
2019-10-01 | 개시 | RBC Capital Mkts | Outperform |
2019-09-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
2019-09-10 | 업그레이드 | Canaccord Genuity | Hold → Buy |
2019-07-23 | 재확인 | Needham | Buy |
2018-12-10 | 개시 | Canaccord Genuity | Hold |
2018-09-21 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
2018-08-09 | 재확인 | Stifel | Hold |
2018-08-07 | 개시 | Stifel | Hold |
2018-08-06 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
2017-10-06 | 재개 | Goldman | Neutral |
모두보기
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
Why ACADIA Pharmaceuticals Inc. stock attracts strong analyst attentionBreakout Momentum Stocks - Metal.it
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - 富途牛牛
What risks could impact ACADIA Pharmaceuticals Inc. stock performanceFree Investment Risk Control - jammulinksnews.com
What drives ACADIA Pharmaceuticals Inc. stock priceHigh-yield portfolio picks - PrintWeekIndia
ACADIA Pharmaceuticals Inc. Stock Analysis and ForecastRobust investment performance - Autocar Professional
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025 - BioSpace
What analysts say about ACADIA Pharmaceuticals Inc. stockPowerful profit generation - Autocar Professional
Is ACADIA Pharmaceuticals Inc. a good long term investmentTremendous return rates - jammulinksnews.com
BofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)’s Price Target To $23, Maintains Neutral Rating - MSN
Bank of America Securities Sticks to Their Hold Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Acadia Debuts New Team, Pipeline With ‘Biotech Powerhouse’ Ambitions - BioSpace
What makes ACADIA Pharmaceuticals Inc. stock price move sharplyFree Step-by-Step Investment Guide - beatles.ru
The $12 Billion Opportunity Bolstering This Biotech Stock - Investor's Business Daily
ACADIA Pharmaceuticals’ SWOT analysis: stock poised for growth amid pipeline expansion - Investing.com Australia
Acadia Pharmaceuticals Rides High On Patent Wins And Strong Pipeline - Finimize
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Acadia CEO sets sights on ‘much more assertive’ deals to invigorate pipeline - BioPharma Dive
ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Acadia Pharmaceuticals' Stocks Undervalue Future Blockbuster Potential - Finimize
ACAD: ACADIA Pharmaceuticals Receives Buy Rating from Needham | ACAD Stock News - GuruFocus
Stocks With Rising Composite Ratings: ACADIA Pharmaceuticals - Investor's Business Daily
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers - Business Wire
Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital - Yahoo Finance
13 Analysts Assess ACADIA Pharmaceuticals: What You Need To Know - Nasdaq
Learn to Evaluate (ACAD) using the Charts - news.stocktradersdaily.com
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent - MSN
ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three years - Yahoo Finance
Bavarian Nordic sells priority review voucher to US healthcare system USD 160m - medwatch.com
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ACAD Stock News - GuruFocus
Neuroscience Leader Acadia Pharmaceuticals Expands Team with 41 New Hires, Awards $4.1M in Stock Options - Stock Titan
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule. - AInvest
Acadia wins patent appeal for key drug composition By Investing.com - Investing.com Nigeria
Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech
US appeals court confirms patent validity of Acadia's Parkinson's drug - MSN
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA
Acadia Pharmaceuticals (ACAD) Secures Patent Win to Maintain Nup - GuruFocus
US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication - Insider Monkey
Acadia Pharmaceuticals Inc (ACAD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):